Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Rajni Kant; Gaurav Dwivedi; Kamran Zaman; Rima R Sahay; Gajanan Sapkal; Himanshu Kaushal; Dimpal A Nyayanit; Pragya D Yadav; Gururaj Deshpande; Rajeev Singh; Sandeep Chaowdhary; Nivedita Gupta; Sanjay Kumar; Priya Abraham; Samiran Panda; Balram Bhargava

doi:10.1093/jtm/taab166

Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

J Travel Med. 2021 Dec 29;28(8):taab166. doi: 10.1093/jtm/taab166.

Authors

Affiliations

¹ Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India.
² Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India.
³ Chief Medical Officer, Community Health Centre, Siddarthnagar, Uttar Pradesh, 272207, India.
⁴ Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India.
⁵ Command Hospital (Southern Command), Armed Forces Medical College, Pune, Maharashtra, 411040, India.

Abstract

The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.

Keywords: Covaxin; Covishield; Heterologous regime; Immunogenecity; SARS-CoV-2.

MeSH terms

COVID-19 Vaccines
COVID-19*
ChAdOx1 nCoV-19*
Humans
SARS-CoV-2
Vaccines, Inactivated

Substances

COVID-19 Vaccines
Vaccines, Inactivated
ChAdOx1 nCoV-19